Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical timolol gel for superficial infantile haemangioma
ACTRN12619001370190Phase 2Recruiting
- Sponsor
- Gillies McIndoe Research Institute
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of timolol in Capillary Haemangioma, sponsored by Gillies McIndoe Research Institute. Primary endpoints: Composite primary efficacy outcome at 52 weeks and Adverse effects: heart rate and blood pressure at 12 months. Started Aug 2018; status: recruiting.
02
Drugs
timolol
03
Conditions
Capillary Haemangioma
Beyond the preview
Go deeper on ACTRN12619001370190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001370190.